Become Affiliate

PepFlow

Download

The Long IGF Analog

IGF-1 LR3

IGF-1 LR3 is a modified insulin-like growth factor 1 analog. The Long R3 name refers to an extended N-terminus and an arginine substitution that are intended to reduce binding to IGF-binding proteins and prolong IGF-style signaling in research systems.

Muscle repairTissue recovery
TierD
EvidencePreliminary
SafetyLimited Data
FDA statusNot Approved
Last reviewed October 25, 2026 23 citations How to read these labels

What is IGF-1 LR3?

IGF-1 LR3 is a modified insulin-like growth factor 1 analog. The Long R3 name refers to an extended N-terminus and an arginine substitution that are intended to reduce binding to IGF-binding proteins and prolong IGF-style signaling in research systems.[1][2][3]

That design makes the molecule biologically interesting, but it also separates it from prescription growth-hormone products and from normal circulating IGF-1 physiology. The key issue is whether this specific analog has route-matched human outcome and safety evidence.[1][2][3]

Product labels often collapse IGF-1, IGF-1 LR3, and research-grade IGF analogs into one category. Those products need separation because potency, binding-protein behavior, exposure, and anti-doping status can differ.[1][2][3] For more context, read the IGF-1 LR3 explainer.

What IGF-1 LR3 is investigated for

IGF-1 LR3 evidence is grouped by practical use case and injectable and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Extended IGF-axis signaling

Injectable

45%Preliminary

Extended IGF-axis signaling is the clearest LR3 mechanism, but it should not be translated into a safe or proven human muscle-growth protocol.[4][5][3][11]

Human evidence

No controlled human LR3 trial establishes that extended IGF-axis signaling improves a clinical or training outcome.[4][5][3]

Animal / mechanistic evidence

Animal studies of IGF-I analogs that bind poorly to IGF-binding proteins report more potent and prolonged biological effects than native IGF-I.[4][5][3]

Muscle growth and recovery support

Injectable

30%Limited

Muscle-growth and recovery claims remain preclinical and mixed, not established lean-mass or recovery therapy.[3][7][1][9]

Human evidence

No controlled human outcome trials for IGF-1 LR3 muscle growth or training recovery were identified in the cited literature.[3][7][1][9]

Animal / mechanistic evidence

Animal work connects long R3 IGF-1 with protein metabolism and somatotropic-axis signaling, while a fetal-sheep growth study did not show a growth benefit.[3][7][1][9]

Training recovery support

Injectable

24%Limited

Training recovery is distinct from muscle growth, while both remain indirect and preclinical.[3][7][1][9]

Human evidence

No controlled human IGF-1 LR3 training-recovery outcome trials were identified in the cited literature.[3][7][1][9]

Animal / mechanistic evidence

Animal protein-metabolism and somatotropic-axis studies provide the recovery rationale, but they do not directly prove post-training repair or performance recovery.[3][7][1][9]

Evidence snapshot

15%

Human evidence

Insufficient

No direct controlled human outcome evidence establishes IGF-1 LR3 for muscle growth, recovery, or body composition. Human relevance is inferred from adjacent IGF-axis literature rather than product-specific results.[1][2][3][6]

30%

Animal / preclinical

Limited

Laboratory and animal evidence supports IGF-axis activity and binding-protein differences. Translation to practical injectable outcomes remains uncertain.[1][2][3][6]

40%

Mechanism support

Preliminary

The analog is designed for persistent IGF-1 receptor activity with reduced binding-protein constraint. That mechanism can affect protein synthesis, glucose handling, and cell-survival pathways, which explains both interest and caution.[1][2][3][6]

Forms & administration

IGF-1 LR3 is offered in injectable research-market products. Nasal delivery remains experimental, with animal-only evidence and no established human regimen. Both forms require their own preparation and exposure assessment, separate from prescription IGF-1 medicines.[9][1][2][8]

InjectableNasal spray

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 20-50 mcg per dose.[9][1][2]

Frequency

Usually taken daily or on training days.[9][1][2]

Timing Considerations

Common timing is morning or after a workout.[9][1][2]

Cycle Length

Common cycles run 4-6 weeks.[9][1][2]

What to expect

First 1-2 weeks

Injectable/systemic IGF-axis exposure may show up as fuller training pumps, appetite shifts, body-weight water movement, and glucose-pattern changes.[1][2][3][6][9]

Weeks 4-6

Injectable/systemic recovery, training load, waist, body weight, and lean-mass appearance may settle into a clearer pattern.[1][2][3][6][9]

After stopping

Pump, fullness, and recovery signals may soften after injectable IGF-1 LR3 exposure ends, while training and nutrition determine whether body-composition changes hold.[1][2][3][6][9]

Safety profile

IGF-1 LR3 safety centers on systemic IGF-axis exposure: glucose symptoms, fluid shifts, growth-factor biology, injectable quality, and sport status matter more than ordinary injection comfort.[11]

Common side effects

Cautions

  • Cancer-biology context[11]
  • Diabetes / glucose control[11]
  • Prohibited in sport[11]

What we don't know

Human dose-response, immunogenicity, long-term metabolic effects, and product interchangeability remain poorly characterized for IGF-1 LR3.[11]

Who IGF-1 LR3 is not for

Route-specific avoid and medical-review notes:

  • Pregnancy or breastfeeding

    Pregnancy or breastfeeding warrants medical review or avoidance for IGF-1 LR3.[1][2][3][6]

  • Active cancer or unexplained growths

    Active cancer or unexplained growths warrants medical review or avoidance for IGF-1 LR3.[1][2][3][6]

  • Diabetes or hypoglycemia risk without clinician oversight

    Diabetes or hypoglycemia risk without clinician oversight warrants medical review or avoidance for IGF-1 LR3.[1][2][3][6]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Insulin / glucose-lowering drugs

    Insulin, sulfonylureas, or other glucose-lowering drugs can intensify or mask glucose symptoms during IGF-axis exposure; this is a GH/insulin-axis caution.[11]

  • GH-axis products

    Somatropin, GHRPs, or GH secretagogues can stack IGF-axis exposure, edema, and glucose effects; this is a theoretical pathway caution.[11]

  • Anabolic hormones

    Testosterone, anabolic agents, or strong bulking stacks can compound edema and growth-signal tracking; this is a theoretical pathway caution.[11]

How it works

IGF-1 LR3 is an IGF-1 analog designed for longer, less binding-protein-constrained IGF-1 receptor signaling than native IGF-1. That receptor pathway can push protein synthesis, glucose handling, cell survival, and tissue-growth signals, which explains the bodybuilding interest and the endocrine risk.[1][2][3][6]

The route caveat is central because the page is about injectable systemic exposure, not a food supplement or approved replacement product. Persistent IGF-axis signaling can overlap with glucose control, organ-growth, cancer-biology, and anti-doping concerns, so product identity and dose matter more than the shorthand name.[1][2][3][6]

Research gaps & open questions

What the current literature has not yet settled about IGF-1 LR3:

01

Controlled trials need to study IGF-1 LR3 itself—not standard IGF-1—and show whether it changes muscle growth, fat loss, strength, or recovery in people.[1][2][3][6]

02

Studies need to show how each route changes exposure and how often IGF-1 LR3 causes low blood sugar or longer-term glucose problems.[1][2][3][6]

03

Independent testing needs to establish whether research-market products contain authentic IGF-1 LR3 at the labeled strength and are free of important impurities.[1][2][3][6]

Common questions

Is IGF-1 LR3 FDA-approved?

No. IGF-1 LR3 has no U.S. FDA approval for injectable drug use; 503A compounding status and WADA concerns are separate issues.[9][10][1][2][13]

Is IGF-1 LR3 the same as IGF-1?

No. It is a modified IGF-1 analog designed for different binding-protein and exposure behavior, so native IGF-1 evidence does not automatically transfer.[9][10][1][2]

Is IGF-1 LR3 proven for muscle growth?

Not proven. Human muscle-growth outcomes for injectable IGF-1 LR3 are not established; the mechanism also raises glucose and growth-signal safety concerns.[9][10][1][2]

Myths & misconceptions

Myth

IGF-1 LR3 is just another growth-hormone peptide.

Reality

It sits downstream in IGF-style signaling and has different metabolic and safety questions from GH secretagogues.[1][2][3][6]

Myth

Longer IGF-style signaling makes it better.

Reality

Longer or stronger pathway activity can also raise exposure and safety concerns.[1][2][3][6]

History & discovery

Long R3 IGF-1 entered the literature as a modified IGF-axis research tool, not as a finished medicine. The modification made it useful for studying IGF receptor signaling when ordinary binding proteins complicate interpretation.[1][2][3][6]

Animal and metabolic studies used IGF-1 LR3 to probe protein metabolism, glucose handling, and growth-factor signaling. That shaped later performance-market interest, but it did not create a controlled human muscle-growth program.[1][2][3][6]

Detection work on a black-market Long R3 IGF-I product shifted the story toward identity, purity, and anti-doping concerns. Market visibility therefore became a safety and enforcement issue, not clinical validation.[1][2][3][6]

Published research23 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Bring consistency to your training goals.

Use PepFlow to record your IGF-1 LR3 protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00